Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms.

Trial Profile

Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Drospirenone (Primary) ; Ethinylestradiol (Primary)
  • Indications Premenstrual dysphoric disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jun 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jul 2014, as reported by ClinicalTrials.gov record.
    • 11 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 17 Jun 2013 Planned End Date changed from 1 Jan 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top